Holen Sie sich die Stockscreener-App
31.49
0.06%
0.06
Schlusskurs vom Vortag:
$31.43
Offen:
$31.55
24-Stunden-Volumen:
72,523
Relative Volume:
0.03
Marktkapitalisierung:
$5.46B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-354.30M
KGV:
-12.48
EPS:
-2.5234
Netto-Cashflow:
$-286.27M
1W Leistung:
-0.16%
1M Leistung:
-14.54%
6M Leistung:
-13.84%
1J Leistung:
+136.64%
1-Tages-Spanne:
$31.20
$31.89
1-Wochen-Bereich:
$30.35
$32.85
52-Wochen-Spanne:
$13.30
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Firmenname
Cogent Biosciences Inc
Sektor
Branche
Telefon
617-945-5576
Adresse
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
31.46 | 5.45B | 0 | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
521.26 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.50 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.78 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.03 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.36 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2025-11-10 | Hochstufung | Stifel | Hold → Buy |
| 2025-11-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-10-16 | Eingeleitet | Stifel | Hold |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-11 | Herabstufung | Needham | Buy → Hold |
| 2024-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Eingeleitet | Citigroup | Buy |
| 2023-12-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-12-08 | Eingeleitet | JP Morgan | Overweight |
| 2023-04-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-09 | Fortgesetzt | Jefferies | Buy |
| 2020-12-23 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
Why (COGT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Cogent Biosciences, Inc. (COGT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance - Yahoo Finance
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative? - Yahoo Finance
Cogent Biosciences (COGT) Stock Price, News & Analysis - Stock Titan
Cogent Biosciences, Inc. (COGT) Stock Analysis: Unveiling A Potential 68% Upside - DirectorsTalk Interviews
Should FDA Filing Acceptance Require Action From Cogent Biosciences Stock Investors? - simplywall.st
Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years - Benzinga
COGT Reiterates by Wedbush -- Price Target Maintained at $55 - gurufocus.com
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with Advanced Systemic Mastocytosis - Investing News Network
COGT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $55 - GuruFocus
Cogent Biosciences (COGT) FDA NDA Acceptance Highlights High P/S Valuation Amid Mixed Insider and Guru Activity - gurufocus.com
FDA Accepts Cogent Biosciences' NDA for Bezuclastinib, COGT Trad - GuruFocus
Cogent Bio wins third FDA review for lead asset (COGT:NASDAQ) - Seeking Alpha
A drug trial found responses in 65% of patients. The FDA will review it. - Stock Titan
Liquidity Mapping Around (COGT) Price Events - Stock Traders Daily
Cogent Biosciences Stock Price Forecast. Should You Buy COGT? - StockInvest.us
How (COGT) Movements Inform Risk Allocation Models - Stock Traders Daily
Cogent Biosciences (COGT) Edges Higher as Buyers Defend Key Support ZoneExtension Target - siam.in
Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia - marketscreener.com
Cogent Biosciences (COGT) inks 5-year drug manufacturing pact - Stock Titan
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com India
$100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today - Benzinga
Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress - Barchart.com
Cogent Biosciences (COGT) Slides 6.5% to $34.67 as Support and Resistance Levels Come into FocusETF Premium Discount - dars.gov.et
Cogent Biosciences Inc. (COGT) Peer Comparison – Compare with Others - Value Research
Cogent Biosciences (NASDAQ: COGT) director schedules option-led stock sale years ahead - Stock Titan
Cogent (COGT) Earnings Report: EPS Falls Short of Its Estimate in the Current Update; After Results: Shares Fall 0.91% in the Latest SessionAnalyst Earnings Estimate - vinanet.vn
Cogent (COGT) Earnings Reading: The Available Earnings Metric Delivers a Miss on the Day; Price Move - vinanet.vn
Cogent (COGT) Earnings Report: EPS Falls Short of Its Estimate in the Current Update; After Results - careplusvn.com
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Cogent Biosciences (COGT) Q2 Update Highlights Valuation Challenges Amid Strong Cash Reserves - GuruFocus
Has Cogent Biosciences (COGT) Run Too Far After Wider Losses? - Sahm
Cogent (COGT) Q1 2026 Earnings: EPS Misses Its Estimate in the Latest Session; Investor Response - careplusvn.com
COGT Maintained by Piper Sandler -- Price Target Raised to $55 - GuruFocus
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - simplywall.st
Discipline and Rules-Based Execution in COGT Response - Stock Traders Daily
Bank of America Corp DE Has $40.18 Million Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences | ARS: Annual Report to Security Holders - Moomoo
Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G - Stock Titan
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
COGT Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Guggenheim raises Cogent stock price target to $52 on FDA decisions - Investing.com
Tema ETFs LLC Acquires 64,898 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cogent Biosciences (COGT) Edges Higher to $38.98, Holding Ground Between Key Technical LevelsSmart Beta Flow - vinanet.vn
Cogent Biosciences (NASDAQ:COGT) Shares Down 5.7%Should You Sell? - MarketBeat
Cogent Biosciences (COGT) Slides 6.81% to $38.70 as Biotech Risk-Off IntensifiesRSI Overbought Alerts - dars.gov.et
Cogent Biosciences Q2 Loss Widens - Moomoo
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results - Investing News Network
Finanzdaten der Cogent Biosciences Inc-Aktie (COGT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
0.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):